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Abstract 
We have developed a Europe-wide approach to investigating the economic impact of 
ME/CFS, facilitating acquisition of information on the economic burden of ME/CFS, and 
international comparisons of economic costs between countries. The economic burden of 
ME/CFS in Europe appears large, with productivity losses most significant, giving scope for 
substantial savings through effective prevention and treatment. However, economic studies of 
ME/CFS, including cost-of-illness analyses and economic evaluations of interventions, are 
problematic due to different, arbitrary case definitions, and unwillingness of doctors to 
diagnose it. We therefore lack accurate incidence and prevalence data, with no obvious way 
to estimate costs incurred by undiagnosed patients. Other problems include, as for other 
conditions, difficulties estimating direct and indirect costs incurred by healthcare systems, 
patients and families, and heterogeneous healthcare systems and patterns of economic 
development across countries. We have made recommendations, including use of the Fukuda 
(CDC-1994) case definition and Canadian Consensus Criteria (CCC), a pan-European 
common symptom checklist, and implementation of prevalence-based cost-of-illness studies 
in different countries using an agreed data list. We recommend using purchasing power 
parities (PPP) to facilitate international comparisons, and EuroQol-5D as a generic measure 
of health status and multi-attribute utility instrument to inform future economic evaluations in 
ME/CFS. 
 
[200 words] 
Keywords:  ME/CFS, economic impact, cost-of-illness studies, economic evaluation, 
healthcare systems. 
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1. Introduction  
 
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a poorly understood, 
serious, complex, multi-system disorder, characterized by symptoms lasting at least six 
months, with severe incapacitating fatigue not alleviated by rest, and other symptoms, many 
autonomic or cognitive in nature, including profound fatigue, cognitive dysfunction, sleep 
disturbances, muscle pain, and post-exertional malaise, which lead to substantial reductions 
in functional activity and quality of life [1,2,3]. Symptomatology, severity and disease 
progression are extremely variable. ME/CFS most commonly occurs between the ages of 20 
to 50, but can affect all age groups, while some three quarters of patients are female [4,5,6]. 
There are no Europe-wide prevalence data, but if the commonly held belief that there are 
some 250,000 sufferers in the UK is correct [7], then there may be some two million patients 
in Europe as a whole.  
 
In terms of estimating the economic costs of ME/CFS, the current state of the art, and its 
historical development, have recently been described by authors EB and LG, who carried out 
a comprehensive literature review [8,9]. The literature was reviewed chronologically and 
detailed the evolution of economic studies of ME/CFS, including cost of illness studies and 
economic evaluations (e.g. cost effectiveness and cost utility analyses) of specific 
interventions. The authors also drew attention to the failure of many patients with the 
condition to be correctly diagnosed, which renders problematic attempts to determine the 
economic burden of the disease. Another problem they identified was that of determining 
direct, indirect and intangible costs in a context where there is lack of agreement over, and 
inconsistent use of, case definitions. This, in turn, is reflected in a lack of agreement 
regarding the incidence and prevalence of the condition. The prevalence in developed 
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countries appears to be within the range of 0.2-1%, but this is highly dependent on case 
definition, while there is published research on ME/CFS in only a small number of countries, 
notably Australia, USA and the UK. Brenna and Gitto [8] concluded that a clearer definition 
of the population prevalence of ME/CFS would make it easier to reach a general consensus 
on its economic burden. This, they argued, would assist the development of appropriate 
guidelines to manage the disease.  
 
In this context, the current classification of ME/CFS in ICD-10 and ICD-10-CM is confusing 
and may contribute to this lack of clarity, since the code G93.3, within ‘Diseases of the 
Nervous System’, specifies ‘postviral fatigue syndrome’ and is applicable to ‘benign myalgic 
encephalomyelitis’, while ‘chronic fatigue syndrome’ is an applicable term within ‘chronic 
fatigue, unspecified’ (R53.82), within the symptoms chapter [10]. The situation may be 
improved by the intended implementation in 2022 of ICD-11, in which it is proposed to list 
‘postviral fatigue syndrome’ in Chapter 08 (Diseases of the nervous system) under the code 
8E49 [11]. While this may create a source of confusion by making an assumption about the 
aetiology of the condition, which cannot always be demonstrated, this is mitigated and 
clarified by the addition of ‘benign myalgic encephalomyelitis’ and ‘chronic fatigue 
syndrome’ as inclusion terms, and of ‘fatigue’ as an exclusion. 
 
In relation to the economic burden of ME/CFS, Brenna and Gitto [8] highlighted that the 
most substantial component is the indirect costs that arise as a result of productivity losses. 
Indeed, attempts have been in the last decade to evaluate the societal costs of ME/CFS, 
especially in terms of occupational outcomes, such as absenteeism, work incapacity, and 
early retirement. For example, estimates in the UK population suggest an average yearly 
productivity loss due to discontinuation of employment of £22,684 per patient in the period 
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2006-2010, with a significant gap between women (£16,130) and men (£44,515) [12]. To 
these figures should be added other direct non-medical costs, such as informal care provided 
by relatives, neighbours or friends, as well as intangible costs related to diminished quality of 
life. The study also highlighted the need to identify common diagnostic criteria and to alert 
policy makers to the overall economic burden of this disease (i.e. its impact on society as a 
whole) and other non-health impacts.  
 
This article reports on work undertaken by Working Group 3 of the European Network on 
ME/CFS (EUROMENE) in the development of a consistent Europe-wide approach to 
investigating the economic impact of ME/CFS. It is structured as follows. It starts with an 
overview of EUROMENE and Working Group 3, followed by a detailed discussion of the 
challenges and issues involved in developing a consistent Europe-wide approach to 
measurement that have been identified by the group. After this, we set out a range of 
recommendations for addressing each of the challenges, while the final section concludes. 
 
2. European Network on ME/CFS (EUROMENE) – A European Cost Action Project 
 
The EUROMENE research network was formally established in 2016 as a collaborative, 
Europe-wide, consortium aiming to address serious gaps in knowledge of ME/CFS. The 
network now involves 22 countries, with four working groups focused on: epidemiology; 
biomarkers and diagnostic criteria; clinical research; and, socio-economics. All working 
groups have the active involvement of researchers from across Europe [13].  
 
The intended long-term impact of the EUROMENE collaboration is that of “preventing 
ME/CFS, determining suitable treatments or avoiding unnecessary treatment in order to 
6 
 
improve patients’ quality of life”. In terms of the rationale for a socio-economic work 
package, we estimated that the annual burden of ME/CFS in Europe, on the basis of 
extrapolation from UK estimates [14], could be in the region of €40 bn if the prevalence and 
cost burden associated with each case were similar to those found in the UK. Therefore, even 
a modest 1% reduction in the overall burden could deliver cost savings of around €400 
million/year, while there may be scope for significantly reducing the economic cost of 
ME/CFS through effective prevention and treatment, though the costs of such initiatives also 
need to be recognised. The EUROMENE Action aims to “promote further research on 
ME/CFS with high economic impact” [15]. 
 
In this context, the terms of reference for Working Group 3 (socio-economics) require it to 
coordinate efforts to determine the societal impact of ME/CFS, to appraise the economic 
implications from the disease, and to do so by enabling the estimation of the burden of 
ME/CFS to society and the provision of long-term trend estimates for societal impact [16]. In 
addition, specific objectives of the working group include: to survey the existing data from 
European countries pertaining to economic losses attributable to ME/CFS; to develop 
approaches to calculating the direct and indirect economic burdens due to ME/CFS; and to 
provide an integrated outcome assessment framework [17]. 
 
3. Challenges in Developing a Consistent Europe-Wide Approach to Measuring the 
Economic Impact of ME/CFS 
 
In this section we describe the progress made by EUROMENE Working Group 3 in the 
development of a Europe-wide approach to investigating the economic impact of ME/CFS. 
We start by setting out an overview of the challenges faced, followed by more in-depth 
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discussion of the most relevant issues. In particular, we focus on challenges relating to case 
definition and prevalence rates, case ascertainment, the determination of costs, as well as 
Europe-wide comparisons. 
 
3.1 Overview of Challenges 
 
As noted above, there are major challenges rendering economic analyses of ME/CFS 
problematic, and these include the use of different case definitions and the unwillingness of 
many doctors to diagnose it. Both of these factors have major impacts on incidence and 
prevalence estimates, while, in addition, we have established that there is a lack of routinely 
collected data which could contribute to such estimates. In particular, since a high proportion 
of patients with ME/CFS remain undiagnosed, there is no obvious way to estimate the costs 
incurred by such patients. Finally, issues arising in respect of international comparisons of the 
economic impact of ME/CFS include the heterogeneous nature of patterns of organisation 
and delivery of health and social care across Europe, differences in the availability of social 
support and welfare benefits the varying levels of economic development and wealth of 
different European countries, and the problem of comparing economic impacts when 
different currencies are in use in different countries, and are subject to variations in exchange 
rates. 
 
Our review of the position regarding the economic impact of ME/CFS has led us to identify a 
number of challenges that need to be addressed if progress is to be made in this area. These 
issues are summarised in Table 1 and are addressed in more detail in the subsequent sub-
sections. 
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Table 1 
Challenges in assessing the economic impact of ME/CFS in Europe 
1. Case 
definition 
ME/CFS is a syndrome, defined in terms of its symptomatology 
rather than its underlying pathology. Work done in this area is 
therefore dependent on case definitions, which of their very 
nature are arbitrary. In addition, there are numerous case 
definitions in use, which vary substantially in sensitivity and 
specificity, and do not necessarily identify the same population. 
2. Incidence and 
prevalence 
Little is known about the incidence or prevalence of ME/CFS. 
Very little work has been done in this area in Europe, except in 
the UK. Conclusions drawn from UK experience, or indeed 
from work done in other countries, in particular the USA and 
Australia, cannot be readily extrapolated to Europe as a whole, 
because the extent of natural variation between populations is 
unknown. 
3. Failure to 
diagnose 
A high proportion of doctors, in particular GPs, refuse to 
recognise ME/CFS as a genuine clinical entity, and as a result 
do not diagnose it. Even in countries where ME/CFS is 
officially recognised, this proportion may be as high as 50%. It 
is not possible therefore to obtain accurate prevalence data 
through the use of service utilisation data. 
4. Determination 
of costs and 
losses 
Any attempt to determine costs and economic losses 
attributable to ME/CFS must take into account direct and 
indirect costs incurred both by healthcare systems, patients and 
families, as well as productivity losses. This applies equally to 
patients who have been diagnosed as having ME/CFS and those 
who have not received a diagnosis, including for the reasons 
outlined in (iii) above. It is likely to be difficult to identify costs 
for this latter group, for obvious reasons. 
5. Variation 
within the 
ME/CFS 
population 
It can be hypothesised that, for example, severely affected 
people (housebound or bedbound) may incur greater overall 
costs than mildly or moderately affected people. There is no 
information available which could shed light on this, which 
clearly requires further research.  
6. Heterogeneity 
of national 
economies 
and health 
care systems 
Against such a background, it is clearly an uphill struggle to 
reach meaningful conclusions about the costs and losses 
attributable to ME/CFS across Europe, particularly given the 
variety of systems of healthcare delivery in Europe, and varying 
stages of economic development. 
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3.2 Case Definition and Prevalence Rates 
 
The major problem in determining the overall economic burden of disease attributable to 
ME/CFS, i.e. little agreement over case definition, has been considered by a number of 
authors. For example, Brurberg et al [18] reviewed the comparability of case definitions and 
identified papers in which different case definitions have been applied to the same patient 
populations, making possible direct comparisons of the impact differences in case definition 
have on apparent prevalence. They listed twenty case definitions developed from 1988 
onwards, which tend to define different populations and which therefore impact significantly 
on the perceived prevalence of the disease, and also levels of severity and hence of need for 
care within the identified patient population. 
 
The case definition most commonly used for research purposes has been that produced by the 
US Center for Disease Control in 1994, otherwise known as the Fukuda definition [19]. More 
recently, the Canadian Consensus Criteria (CCC), which identify a more severely affected 
group of patients than the Fukuda definition, have been widely accepted [3]. A UK study 
found that some 50% of those patients who conformed to the Fukuda definition conformed 
also to the CCC [20], while a parallel study in the UK concluded that there were advantages 
to using both definitions, in order to take advantage of the greater sensitivity of the Fukuda 
definition and the greater specificity of the CCC [21]. A new case definition has been 
proposed by the Institute of Medicine (IOM, 2015) [22] that received international 
recognition. Because of their relative simplicity, the IOM criteria seem useful for screening 
patients in clinical practice, the CCC criteria being used to confirm the diagnosis of ME/CFS. 
Working Group 1 of EUROMENE (Epidemiology) proposes that the Fukuda and CCC 
definitions should be used in all participating European countries [23]. Working Group 3 
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(Socio-economics) accepts this guidance and also recommends use of a symptom checklist, 
enabling data to be collected of such a nature that mapping algorithms can be applied to 
them, enabling conformity to both Fukuda and CCC to be determined. Such a symptom 
checklist was developed by Osoba et al [24]. 
 
A study in three English regions [21] found a prevalence rate of 0.19% conforming to the 
CDC-1994 definition in the age group 18-64, but only 0.10% conforming to the more recent 
Canadian definition [3].  The comparative assessment previously reported by Jason et al in 
2004 [25] found that the Canadian criteria selected cases with less psychiatric co-morbidity, 
more physical functioning impairment, and more fatigue/weakness, neuropsychiatric and 
neurological symptoms than the CDC-1994 definition. Two papers comparing the CDC-1994 
and Australian definitions are cited. Lindal et al, in Iceland, found population prevalences of 
2.1% (CDC-1994) and 7.6 % (Australian) respectively [26], while Wessely et al, in England, 
found that use of the CDC-1994 definition produced a population prevalence of 2.6%, while 
the equivalent figure using the Australian definition was 1.4% [27]. Brurberg et al [18] 
attributed this variation in prevalence obtained using the Australian definition to differences 
in data collection methods; the CDC-1994 definition appeared more robust and less likely to 
be affected by variations in data collection methods. 
 
In conclusion, it is clear that, if comparable data on the economic impact of ME/CFS are to 
be collected across Europe, there needs to be comparable data on the prevalence of the 
illness, and this in turn requires agreement on case definition. Most of the work done to date 
in this area has used the CDC-1994 definition [19], which cannot be ignored because of its 
widespread use in the past, but is not ideal for epidemiology. This is because it was not 
designed for that purpose, but rather to enable well-characterised and relatively homogeneous 
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groups of patients to be identified for clinical trials. As regards cost of illness, one can 
hypothesise that overall costs, at a national level, will appear greater using the more sensitive 
CDC-1994 definition, while costs per case will be greater using the Canadian definition [3]. 
In adopting this two-fold approach, we are acting in concert with the epidemiology and the 
diagnostic methods/biomarkers working groups of EUROMENE. 
 
3.3 Case Ascertainment 
 
As stated above, it is well known that many doctors do not diagnose ME/CFS, further 
complicating the estimation of accurate prevalence data. It also makes it much more difficult 
to determine the economic impact associated with the illness when using service utilisation 
data. 
 
Among the countries participating in the EUROMENE network, the only published work on 
case ascertainment we have been able to identify comes from Ireland, Belgium, Norway and 
the UK. In Ireland, Fitzgibbon et al found that 58% of GPs accepted CFS as a distinct entity 
in 1997 [28], while in Belgium, a survey of patients attending a fatigue clinic concluded that 
only 35% of GPs had experience of CFS, with only 23% having sufficient knowledge to treat 
the condition [29]. A Norwegian study found that the quality of primary care was rated poor 
by 60.6% of ME/CFS patients [30]. In a survey of 811 GPs in South-West England, with a 
response rate of 77%, 48% did not feel confident with making a diagnosis of ME/CFS and 
41% did not feel confident in treatment, though 72% of GPs accepted ME/CFS as a 
recognisable clinical entity [31]. Bayliss et al also found that many GPs lacked confidence 
and knowledge in diagnosing and managing people with ME/CFS [32]. They made available 
to GPs an online training module and an information pack for patients, but nearly half of all 
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patients in their study (47%) failed to receive it. Finally, a study in South Wales concluded 
that the level of specialist knowledge of CFS in primary care was low, and only half the GP 
respondents in their survey believed that the condition actually existed [33]. 
 
As part of our work, we carried out a survey among EUROMENE participants regarding GP 
diagnosis of ME/CFS. Responses were received from Bulgaria, France, Germany, Ireland, 
Italy, Latvia, the Netherlands, Norway, Romania, Spain and the UK, and discussed at 
meetings of the Working Group. Only in Latvia, Norway and the UK was it reported that GPs 
have lists of all registered patients, which could provide denominator data for primary care-
based prevalence studies. In many countries, the proportion of people with ME/CFS 
presenting to a GP was not known. Where estimates were made, these varied from 20% to 
100% per annum. In turn, the proportion of those people with ME/CFS who, having 
consulted a GP, are referred to specialist care, was estimated at about 60% in Latvia and 80% 
in Spain. In France, it was thought that the majority were referred, while in the UK it likely 
varied according to region. The proportion of patients with ME/CFS who self-refer to 
specialist services was thought to be around 30-40% in Latvia and 80% in Spain. In the UK 
the figure was thought to be very low, and in most countries this was not known.  
 
Specialist care is highly variable in nature, and different clinical specialties are involved in 
the different secondary care centres that offer services. In many countries, such services are 
non-existent. There is official guidance on treatment pathways for ME/CFS in Spain, 
Norway, the Netherlands and the UK. In Italy and Latvia, the majority of GPs do not 
recognize ME/CFS as a genuine entity. This is also true of Spain as a whole, though not of 
Catalonia. In France, it is generally regarded as psychological in nature. In both the UK and 
the Netherlands it is officially recognised, though many GPs still refuse to accept this. In 
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Catalonia, GPs were said to be confident in diagnosing ME/CFS, but in Latvia, Norway, the 
Netherlands, France and the UK, there was considerable lack of confidence. The fact that this 
is a diagnosis made essentially through exclusion of other possible diagnoses undoubtedly 
contributes to this. The proportion of patients with ME/CFS who consult their GPs and are in 
fact diagnosed by them was generally said to be low or unknown. In those countries where a 
proportion was estimated (Spain, France, UK), it was thought to be around 20-50%. 
 
Overall, it is clear that, in Europe, a high proportion of GPs, which is likely to be at least 
50%, do not recognise ME/CFS as a genuine clinical entity and therefore do not diagnose it. 
Among those GPs who do recognise its existence, there is a marked lack of confidence in 
making the diagnosis and managing the condition. Therefore, estimates of the public health 
burden of the illness, even where these exist, are likely to underestimate substantially its true 
prevalence. 
 
3.4 Determination of Costs 
 
The overall economic burden of ME/CFS within participating European countries could be 
determined by the implementation of cost of illness studies. These would have to be 
prevalence rather than incidence based, since little is known about the prognosis of the 
disease. There have been Europe-wide cost of illness studies in other conditions, such as 
cancer [34,35], and the output from such studies can be invaluable, both in informing health 
and social care policy, and facilitating the management of health and care services. For 
example, Tarricone states “COI is a descriptive study that can provide information to support 
the political process as well as the management functions at different levels of the healthcare 
organisations. To do that, the design of the study must be innovative, capable of measuring 
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the true cost to society; to estimate the main cost components and their incidence over total 
costs; to envisage the different subjects who bear the costs; to identify the actual clinical 
management of illness; and to explain cost variability. In order to reach these goals, COI need 
to be designed as observational bottom-up studies” [36]. 
 
There have been relatively few cost of illness studies of ME/CFS. Those that exist were 
undertaken in the USA, Australia and the UK, the latter being the only European country 
where such studies have been carried out. Hunter et al [37] compared three such studies, by 
Collin et al [12], McCrone et al [14], and Sabes-Figuera et al [38], and two trials which 
contained cost data, by McCrone et al [39], and Richardson et al [40]. One potential problem 
in comparing the outcomes of such studies arises from the multiplicity of case definitions that 
exist for ME/CFS, as noted earlier. Whereas the cost of illness studies by both Collin et al 
[12] and McCrone et al [14] used the Fukuda definition [19], Sabes-Figuera et al [38] 
undertook a primary care based study of chronic fatigue (not ME/CFS) and used a case 
definition not dissimilar to, but less stringent than, that of NICE [41], which is less restrictive 
than the Fukuda definition [42]. 
 
Other studies which did not meet the inclusion criteria for the 2020 Health report [37] include 
three American studies, by Jason et al [43], Lin et al [44] and Reynolds et al [45]. The study 
by Jason et al was an archive-based database study which used the CDC-1994 definition [43], 
as did the population-based telephone survey by Lin et al [44]. The study by Reynolds et al 
involved analysis of data from a population-based epidemiological study in Wichita, Kansas 
[46], which also used the CDC-1994 (Fukuda) definition. The final cost of illness study 
identified was an Australian population-based study by Lloyd and Pender [47], which 
predated the CDC-1994 definition and used the 1990 Australian definition [48].  
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A further cost of illness study undertaken in the UK by researchers at Sheffield Hallam 
University in 2007 for the charity Action for ME surveyed nearly 3,000 people with ME/CFS, 
recruited through patient organisations. It concluded that, at that time, the total costs of ME/CFS 
could have been over £10,000 p.a. per patient, or £0.6 billion and £2.1 billion per year 
nationally, depending on the prevalence estimate used [49]. More than 90% of this was due to 
loss of income, with NHS healthcare costs quite small in comparison, though it was not made 
clear how cases were defined in the study. 
 
As part of EUROMENE Working Group 3’s activities, a study was undertaken in Latvia to 
explore to what extent the economic burden of ME/CFS could be determined from routinely 
collected process data. In order to do this, authors DA and UB made use of data from the 
Latvian Centre for Disease Prevention and Control (CDPC) and The National Health Service 
(NHS) of Latvia. Patient-related data were classified by ICD-10 code. ICD-10 codes of 
interest for this study were G93.3 Postviral fatigue syndrome, R53 Malaise and fatigue, in 
particular R53.82 Chronic fatigue, unspecified (which is not identified separately in official 
statistics), and B94.8 (Sequelae of other specified infectious and parasitic diseases). CDCP 
data from primary care indicated that approximately 700 patients had ICD-10 code G93.3 
assigned, while there were approximately 15,000 with ICD-10 code R53, and about 70 with 
code B94.8. In toto, these constitute about 0.8% of the Latvian population, which is 
considerably higher than the prevalence found in other comparable populations. Therefore, it 
is likely, though unconfirmed, that the category R53 includes a great many patients with 
illnesses other than ME/CFS. Category G93.3, by contrast, looks like a significant 
underestimate of the true population prevalence. The total of recorded health system costs for 
all these categories in 2017 was €63,893,580, but the authors noted that a great deal of 
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additional data would be required in order to make an accurate determination of the real costs 
to Latvian society of ME/CFS. These included numbers of confirmed ME/CFS diagnoses, 
costs of illness and out of pocket treatment costs per patient, patient reported outcomes, as 
well as the benefits of management of ME/CFS and return on investment [50]. 
 
Overall, on the basis of the activities of Working Group 3 on the determination of costs, we 
believe any attempt to measure societal economic losses attributable to ME/CFS must take 
into account direct and indirect costs incurred both by healthcare systems, patients and 
families, and this applies equally to patients who have been diagnosed as having ME/CFS 
and those who have not received a diagnosis. As noted, it is likely to be difficult to identify 
this latter group, for obvious reasons. Furthermore, we also believe that due to variation 
within the ME/CFS population, it can be hypothesised that, for example, severely affected 
people (housebound or bedbound) may incur greater costs than mildly or moderately affected 
people. There is no information available which could shed light on this, which clearly 
requires further research. 
 
3.5 Europe-Wide Comparisons 
 
A comprehensive review of the financing and organisation of health care in the European 
Union, conducted by WHO for the European Observatory on Health Systems and Policies in 
2009, documented in detail the diversity of such arrangements throughout Europe [51]. 
Similar diversity is found in terms of health outcomes and general levels of health, but no 
correlation was found between accessibility of health care and funding levels in a somewhat 
crude analysis [52]. 
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Against such a background, it is clearly a challenge to reach meaningful conclusions about 
differences in costs and losses attributable to ME/CFS across Europe, particularly given the 
variety of systems of healthcare delivery that exist, as well as varying stages of economic 
development. This is because there is a problem making valid comparisons of health care 
costs between countries which differ markedly in terms of wealth and levels of economic 
development. We propose that, for ME/CFS, purchasing power parity (PPP) adjustments 
should be used in any comparisons. This is a method for comparing the price of goods 
between countries. Using a ‘basket of goods’ of items commonly purchased by consumers, 
such as bread, milk, and shampoo, PPP is a ratio of the total cost of these goods between two 
countries. In this way, one can compare what 1 unit of currency can buy across different 
countries, and convert the values back to a single reference currency [53]. For Europe, the 
obvious choice for the reference currency is the Euro. 
 
In terms of specific data items required for conducting comparable cost of illness studies 
across countries, the need for more comprehensive data collection at the level of the 
individual patient is supported by other sources. Jo [54] has itemised the range and scope of 
the data required to support cost of illness studies, and there may be variation across countries 
in the availability of data items due to differences in the organisation and funding of health 
care. These include the data required to identify both system costs and costs to the individual 
with ME/CFS and those close to him or her. A recent study undertaken in Italy to determine 
costs to the individual assessed the direct and indirect costs of ME/CFS via a questionnaire 
distributed via Italian patient associations [55]. By estimating the cost of medical procedures 
and the cost of lost working time, the study arrived at an estimate for the total economic 
burden of the disease. The questionnaire was discussed in detail by Working Group 3 both in 
terms of its specificity and applicability to different countries. This study could, the Working 
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Group felt, be repeated in other countries, in order to enable the acquisition of data capable of 
direct comparison between countries. The study also aimed to relate the cost impact on 
people with ME/CFS to their clinical condition and the severity of the disease through the use 
of the EuroQol-5D instrument to assess health status [56,57]. An alternative approach to 
achieving this objective could involve the use of instruments for resource use measurement 
[58,59]. 
 
4. Recommendations 
 
Our review has led us to a number of conclusions and recommendations as to how research in 
this area could be advanced. For example, there are a number of serious omissions in the 
availability of data necessary for investigation of the economic impact of ME/CFS and these 
are summarised in Table 2. The main areas of concern relate to: case definition; case 
identification; prevalence and incidence rates; economic cost estimates; data items; and data 
audits.  
 
In addition, a major problem we have identified is the lack of any information on the 
economic impact of severe ME/CFS. For this reason, these patients were necessarily 
excluded from this review, but, since it can be hypothesised that the economic impact of such 
illness is likely to be greater than that of mild or moderate disease, this is clearly a subject 
that requires further investigation. It is of considerable importance that this be confirmed 
empirically, and the scale of any such variation be determined, as a necessary prerequisite to 
the overall determination of the economic impact of ME/CFS in Europe. 
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Table 2 
Summary of Recommendations 
 Area of 
concern 
Recommendation 
1 Case definition That there should be Europe-wide adoption of the Fukuda (CDC-
1994) case definition alongside the Canadian Consensus Criteria 
(CCC). 
2 Case 
identification 
That a common symptom checklist should be used, capable of being 
mapped by algorithms onto both the Fukuda case definition and the 
CCC.  
3 Prevalence and 
incidence 
Better descriptive epidemiological information is required, as a basis 
for economic investigation. This should include information 
concerning the proportion of severely affected people, as there are 
likely to be different cost implications for such people, in 
comparison with those with mild or moderate illnesses. 
4 Economic 
investigation 
Prevalence based cost of illness studies, based on these case 
definitions, should be carried out in different countries, to determine 
the overall cost burden attributable to ME/CFS. 
5 Data items A list of data items required for cost of illness studies has been 
identified (though not reported here). Individual participating 
countries should examine this, to ensure that, insofar as these are 
derivable from routine data collection, that systems are in place to 
ensure that they are collected. 
6 Data audit The availability in participating countries of the relevant data items 
referred to above which are required for cost-of illness studies 
should be examined, with a view to achieving convergence, and 
facilitating international comparisons.  
7 Relationship 
between 
disease 
severity and 
economic 
impact 
The EuroQol-5D instrument [56,57] should be used as a generic 
measure of health status and as a multi-attribute utility instrument to 
determine the relationship, if any, between disease severity and 
economic impacts, as in the Italian study reported in this document 
[55], and to inform future economic evaluations in ME/CFS. We 
further recommend that the Italian study be replicated in other 
countries, to enable international comparisons to be made. 
8 International 
comparisons 
and 
compilation of 
Europe-wide 
statistics 
Given the diversity of patterns of health care organisations and 
funding health, as well as of outcomes and general levels of health, 
as well as of national wealth and levels of economic development, 
we recommend the use of purchasing power parities (PPP) in order 
both to make valid international comparisons and to collate 
meaningful statistics at a European level. 
 
 
 
 
20 
 
5. Conclusion 
 
Problems impeding research into the economic impacts of ME/CFS in Europe include those 
of arbitrary case definitions, incomplete and inadequate information on incidence and 
prevalence, failure to diagnose the condition on the part of a high proportion of doctors, and 
how to determine costs and losses, given variation within the ME/CFS population (e.g. 
between severely affected and mildly or moderately affected patients, with different cost 
implications for each of these categories). There are also important issues relating to the 
heterogeneity of national economies and health care systems within Europe. As a result, we 
have made a set of recommendations concerning how further progress might be made in this 
area, in particular in relation to case definition, case identification, descriptive epidemiology, 
methods of economic investigation, data items required to support such investigation, data 
audit of quality and completeness, and international comparisons and the compilation of 
Europe-wide statistics. The relationship between disease severity and economic impact 
should be a high priority for future research. 
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